Wells Fargo & Company MN Has $128,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Wells Fargo & Company MN grew its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 16.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 16,644 shares of the company’s stock after acquiring an additional 2,402 shares during the period. Wells Fargo & Company MN’s holdings in iTeos Therapeutics were worth $128,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in iTeos Therapeutics by 1.2% in the third quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company’s stock valued at $4,771,000 after purchasing an additional 5,368 shares during the last quarter. Empowered Funds LLC increased its stake in shares of iTeos Therapeutics by 5.0% in the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock valued at $530,000 after buying an additional 3,305 shares during the period. Virtu Financial LLC boosted its position in iTeos Therapeutics by 84.3% during the 4th quarter. Virtu Financial LLC now owns 18,493 shares of the company’s stock worth $142,000 after buying an additional 8,460 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in iTeos Therapeutics during the 4th quarter worth approximately $142,000. Finally, US Bancorp DE increased its position in iTeos Therapeutics by 40.1% in the 4th quarter. US Bancorp DE now owns 16,919 shares of the company’s stock valued at $130,000 after acquiring an additional 4,843 shares during the period. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $6.68 on Friday. The stock has a market capitalization of $255.67 million, a P/E ratio of -2.12 and a beta of 1.39. The business has a 50 day simple moving average of $6.55 and a 200 day simple moving average of $7.44. iTeos Therapeutics, Inc. has a one year low of $4.80 and a one year high of $18.70.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.14. Equities analysts expect that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. cut their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. Wedbush reiterated an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. Wells Fargo & Company lowered their price objective on iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Tuesday, April 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Thursday, March 6th.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.